A Phase 4 interventional study of Infliximab in Crohn Disease, sponsored by Taizhou Mabtech Pharmaceutical Co.,Ltd. Recruiting at 1 site in China. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Taizhou Mabtech Pharmaceutical Co.,Ltd · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies testing infliximab in Crohn Disease — 10 open to participants now, 11 under way, 1 of them phase 3. Infliximab · Crohn Disease.
Among the 42 studies testing infliximab in Crohn Disease, this one is the 32nd largest by planned enrollment of the 41 interventional ones that give a count, is one of 4 that started in 2023, is one of 21 in phase 4, reaches primary completion later than 6 of the 10 other live ones, and was the 38th registered.
1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.
Browse Crohn Disease studies →10 of the 42 studies testing infliximab in Crohn Disease are open now, in 7 countries. Recruiting first, the newest first:
Pontificia Universidad Catolica de Chile · Sites in Chile
Ages 18–75
Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW · Sites in Belgium
Ages 18+
Asan Medical Center · Sites in Korea, Republic of
Ages 18–100
Erasmus Medical Center · Sites in Netherlands
Ages 1–15
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Sites in Netherlands
Ages 18–80
By country, each count listing its studies:
Infliximab: first FDA approval 1998 (REMICADE), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →
Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.
This study: 6 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 12 · Phase 4 21
First in 1995; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 67 across 1,262 interventional studies indexed under Crohn Disease.
Median enrollment 100 across the 41 interventional studies. Of the 28 that completed or were terminated, 10 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 42 have an industry lead sponsor. The 10 most frequent:
Taizhou Mabtech Pharmaceutical Co.,Ltd is the lead sponsor of 18 studies on the registry; 4 are open to participants now.
Taizhou Mabtech Pharmaceutical Co.,Ltd has 1 study filed under Crohn Disease — fewer than ten, so there is no comparison to draw.
3 of the studies testing infliximab in Crohn Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05906576Taizhou Mabtech Pharmaceutical Co.,LtdPost-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients | 2026-11 |
| NCT06064864Asan Medical CenterEfficacy and Safety of Formulation Switching Between SC Infliximab and IV Infliximab in Patients With CD | 2026-12-31 |
| NCT06758024Pontificia Universidad Catolica de ChilePROactive and Early Infliximab Monitoring and oPTimization in Inflammatory Bowel Disease | 2027-03 |
Add all 3 to your calendar (.ics) → With an account.
Among the 42 studies testing infliximab in Crohn Disease, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Post-marketing registration of Infliximab for injection in Chinese pediatric Crohn's disease patients.
This is a prospective, multicenter registry study in Chinese pediatric Crohn's disease patients. A total of 30 subjects were planned to be enrolled and treated with Infliximab. Subjects were observed for 102 weeks after administration to evaluate the clinical efficacy and safety of infliximab in the treatment of children with Crohn's disease in a real diagnostic setting.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Infliximab for the treatment of Crohn's disease in children
Drug: Infliximab
Infliximab in the treatment of Crohn's disease in children
Also known as: CMAB008
Clinical response rate at 14 weeks
Clinical response: PCDAI decreased ≥15 points and total PCDAI≤ 30 points
Time frame: up to 14 weeks
Clinical remission rate at week 14 and 54
Clinical remission: PCDAI≤10
Time frame: up to 54 weeks
Endoscopic response rate at week 14 and 54
Endoscopic response: SES-CD decreased ≥ 50%
Time frame: up to 54 weeks
Mucosal healing rate at week 14 and 54
Mucosal healing: SES-CD 0-2
Time frame: up to 54 weeks
Changes from baseline in height-for-age z-score (HAZ), weight-for-age z-score (WAZ) and BMI-for-age z-score at week 14 and 54
The z-score is converted from anthropometric measurements based on the World Health Organization growth reference. The z-score including: height-for-age z-score (HAZ), weight-for-age z-score (WAZ) and BMI-for-age z-score.
Time frame: up to 54 weeks
Changes from baseline in serum C-reactive protein at week 14 and 54
Changes from baseline in serum C-reactive protein at week 14 and 54
Time frame: up to 54 weeks
Changes from baseline in erythrocyte sedimentation rate at week 14 and 54
Changes from baseline in erythrocyte sedimentation rate at week 14 and 54
Time frame: up to 54 weeks
Changes from baseline in the rate of delayed development of adolescents at 14 and 54 weeks
Delayed development: Female children over 13 years old and male children over 14 years old are in the Tanner stage I
Time frame: up to 54 weeks
ADA positive rate
ADA positive rate at week 14 and 54
Time frame: up to 54 weeks
Percentage of participants with Adverse Events
Total Frequency of Adverse Events/Serious Adverse Events Within the Whole Time of the Study
Time frame: up to 102 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2023 (actual). Primary completion is estimated for Nov 2026, 38 months after the start.
Of 70 phase 4 interventional studies under Crohn Disease, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 68. This study's planned 38 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Infliximab
Taizhou Mabtech Pharmaceutical Co.,Ltd